Tocilizumab, the IL-6 inhibitor, may be used for CRS management either alone or in conjunction with corticosteroids and dosing interruption, especially for patients that are refractory to drug cessation and corticosteroids (10, 108–110). The gene discussed is IL6; the disease is congenital rubella syndrome.